GlassScriptPhysician profile
Ashley Korosa
NPI 1366900649
$2,850.68
in general payments reported to CMS, 2019-2025
20 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $508 · 2022: $755 · 2023: $603 · 2024: $544 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $523.22 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $442.33 | 2022-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $361.32 | 2021-2025 | Penmenvy |
| Sanofi Pasteur INC. | $281.47 | 2022-2025 | |
| Novo Nordisk INC | $237.98 | 2021 | |
| Tris Pharma INC | $140.38 | 2021-2022 | |
| Neos Therapeutics, LP | $130.31 | 2022-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $120.85 | 2021-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Cranial Technologies, INC | $110.71 | 2022-2025 | Doc Band |
| Abbvie INC. | $100.27 | 2022 | |
| Sobi, INC | $77.95 | 2022-2023 | |
| Collegium Pharmaceutical, INC. | $59.28 | 2025 | Jornay Pm |
| Genentech USA, INC. | $56.92 | 2021-2022 | |
| Aytu Biopharma, INC. | $47.88 | 2024 | Karbinal |
| Adlon Therapeutics L.P. | $45.10 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $29.84 | 2021-2022 | |
| Seqirus USA INC | $28.54 | 2022-2023 | Flucelvax Quadrivalent |
| Pfizer INC. | $20.76 | 2023 | |
| Vertical Pharmaceuticals, LLC | $18.10 | 2024 | Relexxii |
| Sanofi-Aventis U.S. LLC | $17.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Korosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.